Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$ABIO Announces Patent for Bucindol (Gencaro)

|Includes: ARCA biopharma, Inc. (ABIO)
ARCA Biopharma, Inc. (NASDAQ: ABIO) is a biopharmaceutical company focused on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States.

$ABIO is up on massive volume of more than 20 million shares, which, for this stock, is more than 850 times its 3 month average volume.

What’s so special about $ABIO? This morning, $ABIO announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with Bucindolol based on genetic testing.

The student body knows that The Dean’s big on patents, especially when it comes to pharma companies. The parent, U.S. #7,678,824, “Methods for Treatment with Bucindol Based on Genetic Testing,” provides protection for $ABIO’s novel approach to treating patients with heart failure.

The press release detailing this development suggests that approximately 5.7 million Americans have heart failure and nearly 670,000 new patients are diagnosed each year.

Additionally, heart failure is believed to be the underlying cause for approximately 12 million to15 million annual visits to physicians, 6.5 million annual hospital days and more than $37 billion in healthcare costs in the United States alone.

So far today, $ABIO has traded as high as $9.11 per share, or 243%, since yesterday’s close of$2.65.

Since The Dean cannot officially recommend, he wants his students to think about his favorite expression, “The Trend is Your Friend!

Disclosure: none